Literature DB >> 16353143

Enhancement of human papilloma virus type 16 E7 specific T cell responses by local invasive procedures in patients with (pre)malignant cervical neoplasia.

Jeroen Visser1, Debbie van Baarle, Baukje Nynke Hoogeboom, Nathalie Reesink, Harry Klip, Ed Schuuring, Esther Nijhuis, Michael Pawlita, Laura Bungener, Jacqueline de Vries-Idema, Hans Nijman, Frank Miedema, Toos Daemen, Ate van der Zee.   

Abstract

It has been suggested that local invasive procedures may alter the natural course of (pre)malignant cervical disease. This could be due to partial excision of the lesions, or via induction of cellular immunity against human papillomavirus (HPV) by the local invasive procedures. We studied the influence of local invasive procedures on HPV-16 E7 specific immune responses in patients with different grades of cervical intra-epithelial neoplasia (CIN) and different stages of cervical cancer. Blood was obtained at intake and after invasive procedures from patients with CIN or cervical cancer. Antigen specific T-cell responses were measured by IFN-gamma ELISPOT analysis, after stimulation with recombinant HPV-16 E7 protein. As expected, HPV-16 E7 specific IFN-gamma T cell responses were more frequent in HPV-16 DNA positive patients compared with that in HPV-16 DNA negative patients (39/50 vs. 16/36, (p=0.006, chi2 test). After invasive procedures, a small number of HPV-16 DNA positive CIN patients, but a considerable proportion of HPV-16 DNA positive cervical cancer patients, showed an enhancement of T cell responses against HPV-16 E7. Induction of T cell reactivity was most pronounced in cervical cancer patients who had undergone previous invasive procedures. Both CD4+ and CD8+ T cells showed E7 specific IFN-gamma production upon in-vitro stimulation. Our study shows that invasive procedures may enhance HPV-specific cell-mediated immunity in a considerable number of patients with cervical cancer, but in only a minority of CIN patients. Our data indicate that invasive procedures should be considered as possible confounding factors when analyzing the effectiveness of therapeutic immunization studies, especially, when induction of HPV-specific immune responses is used as intermediate end-point. Copyright (c) 2005 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16353143     DOI: 10.1002/ijc.21673

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  6 in total

Review 1.  Human Immunodeficiency Virus and Human Papilloma Virus - why HPV-induced lesions do not spontaneously resolve and why therapeutic vaccination can be successful.

Authors:  Sjoerd H van der Burg; Joel M Palefsky
Journal:  J Transl Med       Date:  2009-12-18       Impact factor: 5.531

2.  Increase of human papillomavirus-16 E7-specific T helper type 1 response in peripheral blood of cervical cancer patients after radiotherapy.

Authors:  Félix Giovanni Delgado; Elizabeth Martínez; María Angélica Céspedes; María Mercedes Bravo; María Cristina Navas; Alba Lucía Cómbita Rojas
Journal:  Immunology       Date:  2008-09-05       Impact factor: 7.397

3.  Frequencies and role of regulatory T cells in patients with (pre)malignant cervical neoplasia.

Authors:  J Visser; H W Nijman; B-N Hoogenboom; P Jager; D van Baarle; E Schuuring; W Abdulahad; F Miedema; A G van der Zee; T Daemen
Journal:  Clin Exp Immunol       Date:  2007-11       Impact factor: 4.330

4.  Serological response to an HPV16 E7 based therapeutic vaccine in women with high-grade cervical dysplasia.

Authors:  Koenraad Van Doorslaer; Laura L Reimers; Yevgeniy Y Studentsov; Mark H Einstein; Robert D Burk
Journal:  Gynecol Oncol       Date:  2009-06-24       Impact factor: 5.482

5.  Immunomodulation to enhance the efficacy of an HPV therapeutic vaccine.

Authors:  Claire Smalley Rumfield; Samuel T Pellom; Jeffrey Schlom; Caroline Jochems; Y Maurice Morillon Ii
Journal:  J Immunother Cancer       Date:  2020-06       Impact factor: 13.751

6.  Immunotherapy of human papilloma virus induced disease.

Authors:  Sjoerd H van der Burg
Journal:  Open Virol J       Date:  2012-12-28
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.